Clinical trials: Regional Citrate Anticoagulation (RCA)
Intensive Care Unit Syndrome
Ionized Magnesium for Monitoring of Citrate-anticoagulated CVVHD
It has been reported in several studies that ionized hypomagnesemia is associated with higher morbidity and mortality rates. During continuous renal replacement therapy with regional citrate anticoagulation (CRRT-RCA), the loss…
- Trial name
- MagiCC (NCT04412980)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
AKI - Acute Kidney Injury, CKD 5D, Hemodialysis
Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment
The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism…
- Conditions
- AKI - Acute Kidney Injury, CKD 5D, Hemodialysis, Hepatic Failure
- Trial name
- PRECISE (NCT07579663)
- Testing
- Two-stage calcium supplementation in RCA-CRRT, Commercial RCA-CRRT module
- Volunteers
- 142 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Continuous Renal Replacement Therapy, Hyperlactatemia
RCA for CRRT in Hyperlactatemia Patient With Increased Bleeding Risk
The purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk.
- Conditions
- Continuous Renal Replacement Therapy, Hyperlactatemia, Bleeding
- Trial name
- NCT04315623
- Testing
- Regional citrate anticoagulation CRRT, No-anticoagulation CRRT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Air Force Military Medical University, China
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit.
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
- Trial name
- NCT05399537
- Testing
- Prismocitrate 18, PrisMax System Version 3.x with calcium line accessory
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vantive Health LLC
Liver Failure
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
The purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in patients with liver failure and high risk bleeding.
- Trial name
- NCT03791190
- Testing
- Regional citrate anticoagulation, No-anticoagulation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Air Force Military Medical University, China
Acute Kidney Injury
Comparison of RCA and RACD in Extra-renal Purification by SLED
One of the main RRT issues is anticoagulation of the ECC, because blood contact with biomaterials causes bio-incompatibility reactions, including activation of the coagulation cascade.
- Trial name
- ARDC-SLED (NCT04968587)
- Testing
- Sustained Low-Efficiency Dialysis
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Groupe Hospitalier Sud Ile-de-France
Acute Kidney Injury, Renal Failure
Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation
The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments.
- Trial name
- RCA-Flux (NCT07679568)
- Testing
- multiFlux 160 hemofilter with regional heparin anticoagulation, multiFlux 160 hemofilter with RCA with regional citrate anticoagulation, multiFlux 130 hemofilter with regional heparin anticoagulation
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT).
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
- Trial name
- NCT02860130
- Testing
- Prismocitrate 18, No Anticoagulation
- Where
- 12 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Vantive Health LLC
Acute Kidney Failure With or Without:, MODS
Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT
1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors. 2. To validate a pharmacokinetic model which has been established in a formal paper.
- Conditions
- Acute Kidney Failure With or Without:, MODS, Sepsis, Hepatic Insufficiency
- Trial name
- NCT00948558
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital